SearchDictionaryMobileLogin

Kadri Altundag Selected Research

Breast Neoplasms (Breast Cancer)

12/2008Response to taxanes in triple negative breast cancer.
07/2008Weekly paclitaxel in the adjuvant treatment of breast cancer.
05/2008Vitamin D intake may be a predictor of response to aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
04/2008Vitamin D supplementation and response to aromatase inhibitors in postmenopausal women with hormone-receptor positive breast cancer.
01/2008Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines.
01/2008Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer.
12/2007Vitamin D intake and breast cancer risk in postmenopausal women.
12/2007Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.
11/2007Bone mineral density in breast cancer patients with estrogen receptor-negative tumor.
08/2007Hormone receptor status as a prognostic factor in breast cancer patients with hepatic metastases treated by liver resection.
07/2007Influence of smoking history on breast cancer prognosis: retrospective study of 240 operable breast cancer patients who received adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil chemotherapy regimen.
06/2007Re: Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.
04/2007Potential chemotherapy options in the triple negative subtype of breast cancer.
03/2007Hormone receptor status as an independent variable affecting the survival of advanced breast cancer patients with brain metastases.
01/2007Bisphosphonates may also be effective in the management of non-skeletal metastases in hormone receptor positive breast cancer.
01/2007CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
09/2006Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
08/2006Angiotensin 1-7 and risk for breast cancer recurrence.
06/2006Aromatase inhibitors in breast cancer: an overview.
05/2006Which is better in neoadjuvant treatment of breast cancer? Taxane followed by anthracyline or vice versa.
04/2006Coffee and breast cancer risk.
01/2006Neoadjuvant chemotherapy with weekly paclitaxel in breast cancer patients may increase release of cancer cells into circulation by decreasing interstitial fluid pressure.
01/2006Weekly paclitaxel may improve locoregional recurrence by decreasing interstitial fluid pressure in operable node-positive breast cancer patients.
01/2006Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor.
01/2006Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors.
01/2006Low incidence of mamographically detected microcalcification in breast cancer patients with lobular histology may be attributed to low levels of osteopontin.
12/2005Heparanase activity and bone loss in postmenopausal breast cancer patients.
12/2005Is there an association between high heparanase level and osteoporosis risk in breast cancer patients without clinical evidence of bone metastases?
11/2005Hormone receptor status of primary tumor as a prognostic factor in patients with liver metastases from breast cancer treated with transcatheter arterial chemoembolization.
10/2005Rationale for the use of trastuzumab in patients with cerebral metastases who previously receive trastuzumab-based therapy for metastatic breast cancer.
04/2005Hormone receptor status in patients with breast cancer and liver metastases treated with laser-induced intersititial thermotherapy.
04/2005Insulinlike growth factor-1 receptor: predictive factor in breast cancer patients treated with trastuzumab?
02/2005Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer.
01/2005A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer.
01/2005Pure and mixed hormone receptor positive breast tumors: are they different from therapeutic point of view?
01/2005Tamoxifen may increase insulin requirement in breast cancer patients with type 1 diabetes mellitus through its agonistic activity on splenic endothelial cells and inhibitory effect on pancreatic beta cells.
01/2005Endogenous estrogen levels, bone mineral density and estrogen receptor status in breast cancer.
01/2005SRL172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients.
01/2005Does paclitaxel decrease the interstitial fluid pressure and improve oxygenation in breast cancer in a schedule-dependent fashion?
07/2004Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients.
04/2004Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability?
01/2004Possible interaction between activator protein-1 and proto-oncogene B-cell lymphoma gene 6 in breast cancer patients resistant to tamoxifen.
01/2004DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients.
01/2004Addition of granulocyte-colony stimulating factor (G-CSF) to adjuvant treatment may increase survival in patients with operable breast cancer: interaction of G-CSF with dormant micrometastatic breast cancer cells.
01/2004Addition of granulocyte-colony stimulating factor (G-CSF) may further increase chemosensitive state in premenopausal node-positive breast cancer patients with induced angiogenesis after surgery.
12/2003Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.

Articles by Research Topic

Disease

46Breast Neoplasms (Breast Cancer)
12/2008 - 12/2003
13Neoplasm Metastasis (Metastasis)
04/2008 - 01/2004
9Neoplasms (Cancer)
06/2008 - 01/2005
9Carcinoma (Carcinomatosis)
04/2008 - 01/2004
9Small Cell Carcinoma
08/2006 - 04/2004
3Osteonecrosis (Kienbock's Disease)
06/2008 - 06/2006
3Noninfiltrating Intraductal Carcinoma (DCIS)
08/2007 - 07/2005
3Head and Neck Neoplasms (Head and Neck Cancer)
01/2007 - 01/2005
3Lung Neoplasms (Lung Cancer)
01/2007 - 08/2004
3Glioblastoma (Glioblastoma Multiforme)
07/2005 - 01/2005
2Lymphoma (Lymphomas)
07/2007 - 04/2004
2Multiple Myeloma
01/2007 - 06/2006
2Stroke (Strokes)
01/2007 - 11/2006
2Oropharyngeal Neoplasms
01/2006 - 01/2004
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/2005 - 04/2004
2Adenocarcinoma
06/2005 - 01/2005
2Colorectal Neoplasms (Colorectal Cancer)
01/2005 - 11/2003
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2007
1Hypersensitivity Vasculitis (Leukocytoclastic Angiitis)
12/2007
1Necrosis
12/2007
1Arthralgia (Joint Pain)
12/2007
1Protein S Deficiency (Deficiency, Protein S)
12/2007
1Infection
07/2007
1Alzheimer Disease (Alzheimer's Disease)
01/2007
1Hypertension (High Blood Pressure)
12/2006
1Galactorrhea
02/2006
1Hepatocellular Carcinoma (Hepatoma)
01/2006
1Osteoporosis
12/2005
1Budd-Chiari Syndrome (Budd Chiari Syndrome)
11/2005
1Contracture
11/2005
1Thymoma (Thymic Carcinoma)
07/2005
1Renal Cell Carcinoma (Grawitz Tumor)
02/2005
1Prostatic Neoplasms (Prostate Cancer)
01/2005

Drug/Important Bio-Agent (IBA)

11trastuzumab (Herceptin)FDA Link
01/2008 - 01/2004
9Paclitaxel (Taxol)FDA LinkGeneric
07/2008 - 07/2004
9HormonesIBA
05/2008 - 01/2005
7Fluorouracil (Carac)FDA LinkGeneric
07/2007 - 11/2003
6Aromatase InhibitorsIBA
05/2008 - 10/2004
6Estrogens (Estrogen)FDA Link
11/2007 - 01/2005
5DiphosphonatesIBA
06/2008 - 01/2005
5Vitamin DFDA LinkGeneric
05/2008 - 01/2004
5Epidermal Growth Factor Receptor (EGF Receptor)IBA
12/2007 - 06/2005
4Cyclophosphamide (Cytoxan)FDA LinkGeneric
07/2007 - 01/2005
4Cisplatin (Platino)FDA LinkGeneric
01/2007 - 01/2004
4zoledronic acid (zoledronate)FDA Link
11/2006 - 09/2004
4TamoxifenFDA LinkGeneric
01/2005 - 12/2003
3iodonitrotetrazolium (INT)IBA
04/2008 - 07/2005
3imatinib (Gleevec)FDA Link
11/2005 - 01/2005
2Aromatase (CYP19)IBA
12/2007 - 01/2006
2albumin-bound paclitaxelFDA Link
08/2007 - 12/2006
2Doxorubicin (Adriamycin)FDA LinkGeneric
07/2007 - 01/2004
2Pentoxifylline (Trental)FDA LinkGeneric
01/2007 - 01/2006
2alpha-TocopherolFDA Link
01/2007 - 01/2006
2Epirubicin (Ellence)FDA LinkGeneric
01/2007 - 01/2005
2Cadherins (E-Cadherin)IBA
06/2006 - 01/2004
2heparanaseIBA
12/2005 - 12/2005
2CalciumIBA
05/2004 - 01/2004
2letrozole (Femara)FDA Link
04/2004 - 12/2003
2Granulocyte Colony-Stimulating Factor (G-CSF)IBA
01/2004 - 01/2004
1TaxoidsIBA
12/2008
1dasatinib (BMS 354825)FDA Link
01/2008
1anastrozole (Arimidex)FDA Link
12/2007
1Warfarin (Coumadin)FDA LinkGeneric
12/2007
1Protein CIBA
12/2007
1erbB-2 Receptor (Receptor, erbB 2)IBA
08/2007
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
08/2007
1Progesterone Receptors (Progesterone Receptor)IBA
08/2007
1rituximab (Mabthera)FDA Link
07/2007
1Dietary Fats (Ghee)IBA
06/2007
1AntioxidantsIBA
01/2007
1Testosterone (Sustanon)FDA LinkGeneric
01/2007
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
12/2006
1Caveolin 1IBA
12/2006
1bevacizumabFDA Link
12/2006
1angiotensin I (1-7)IBA
08/2006
1gefitinib (Iressa)FDA Link
08/2006
1CoffeeIBA
04/2006
1OsteopontinIBA
01/2006
1Selective Estrogen Receptor Modulators (SERM)IBA
01/2006
1Papillomavirus Vaccines (HPV Vaccines)IBA
01/2006
1gemtuzumab (gemtuzumab ozogamicin)FDA Link
11/2005
1Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
11/2005
1Proto-Oncogene Proteins c-kit (Proto-Oncogene Protein c-kit)IBA
11/2005
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
09/2005
1Phosphotransferases (Kinase)IBA
08/2005
1Interleukin-6 (Interleukin 6)IBA
02/2005
1C-Reactive ProteinIBA
02/2005
1Mitoxantrone (Novantrone)FDA LinkGeneric
02/2005
1CytokinesIBA
02/2005
1ChemokinesIBA
02/2005
1Insulin (Novolin)FDA Link
01/2005

Therapy/Procedure

8Drug Therapy (Chemotherapy)
04/2008 - 01/2004
1Tooth Extraction (Tooth Extractions)
01/2007
1Neck Dissection (Radical Neck Dissection)
01/2007
1Neoadjuvant Therapy
05/2006
1Mammaplasty (Breast Reconstruction)
02/2006
1Adjuvant Chemotherapy
12/2005
1Breast Implants (Breast Implant)
11/2005
1Induced Hyperthermia (Thermotherapy)
04/2005
1Lasers (Laser)
04/2005